TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The panel will focus on the development of T cell receptor (TCR)-engineered therapies for cancer treatment. A live webcast can be accessed through the Company’s website, with an archived replay available for 30 days post-event. TScan's lead candidates, TSC-100 and TSC-101, target hematologic malignancies while expanding their ImmunoBank for solid tumor therapies.

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a panel discussion at the Cowen 43^rd Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 8, 2023, at 2:10 p.m. Eastern Time.

A webcast of the panel will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com

FAQ

When is TScan Therapeutics participating in the Cowen 43rd Annual Health Care Conference?

TScan Therapeutics will participate in the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET.

How can I watch the TScan Therapeutics panel discussion?

You can watch the TScan Therapeutics panel discussion live via webcast on the Company’s website.

What are the main focuses of TScan Therapeutics?

TScan Therapeutics focuses on developing T cell receptor (TCR)-engineered therapies for treating cancer.

What are TScan Therapeutics' lead therapy candidates?

TScan's lead therapy candidates are TSC-100 and TSC-101, aimed at treating hematologic malignancies.

Where will the Cowen 43rd Annual Health Care Conference be held?

The Cowen 43rd Annual Health Care Conference will be held at the Boston Marriott Copley Place in Boston, MA.